瞄准“首创”“首发”“首用” 多地抢抓创新药械产业机遇

Group 1 - The Chinese government is accelerating the development of a world-class innovative pharmaceutical and medical device industry, aiming for breakthroughs in "first-in-class" drugs and products [1] - Jiangsu Province has received approval for a plan to develop a biopharmaceutical industry cluster with global influence, focusing on high-level openness and institutional innovation [1][2] - By 2027, the biopharmaceutical industry in Pudong is expected to exceed 500 billion yuan, with innovative pharmaceutical and medical device output accounting for 35% to 40% [2] Group 2 - Hainan Province has introduced comprehensive policies to support the high-quality development of the biopharmaceutical industry, including financial rewards for R&D and participation in national procurement [2][3] - The Chinese biopharmaceutical industry is entering a critical phase characterized by policy empowerment, regional competition, and innovation breakthroughs, as indicated by the national strategic planning [3] - The number of innovative drugs in development in China accounts for approximately 30% of the global total, positioning the country as the second-largest pharmaceutical market worldwide [3][4] Group 3 - Chengdu is emerging as a hub for innovative drug development, with significant investments and a growing number of projects in the biopharmaceutical sector [4] - The Tianfu International Biotech City in Chengdu has attracted over 300 projects with total investments exceeding 140 billion yuan, fostering a talent pool of nearly 20,000 [4] - The competition for becoming a biopharmaceutical innovation hub is seen as a new avenue for regional economic development, with potential for creating internationally competitive enterprises [4][5]